Back to search results

Observational Study of Melanoma Bio-specimens

This observational study aims to understand the biological changes that happen when melanoma (a type of skin cancer) starts and grows. Researchers will collect tissue and blood samples from people with melanoma. Tissue will come from a previous biopsy (a procedure to remove a small piece of tissue for examination) or a planned biopsy. About 3-4 teaspoons of blood will also be collected. The study is looking for changes in a specific mechanism called RAF in the melanoma tissue over 10 years. You can join if you are 18 or older, have a confirmed diagnosis of melanoma, and have tissue available from a test or procedure, or have already had such a procedure. The study plans to enroll 3000 participants, but its current status is unclear.

Study design
This is an observational study planning to enroll 3000 participants. It is not testing a specific treatment, but rather collecting information.
What's involved
You would provide tissue from a previous or planned biopsy and about 3-4 teaspoons of blood.
Compensation
Not stated in the trial record.
Follow-up
Researchers will look at molecular changes in your melanoma tissue for up to 120 months (10 years).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01205815

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

Recruiting
Not specifiedAges 18+Observational
Vanderbilt-Ingram Cancer Center
~3,000 participants
Updated 2025-09-19 on ClinicalTrials.gov
What's tested:Tissue and blood collection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Molecular changes in patients' melanoma tissue
Measured over at 120 months

Conditions

Melanoma

Explore related trials

Melanoma

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Douglas Johnson, M.D. · PRINCIPAL_INVESTIGATOR · Vanderbilt-Ingram Cancer Center

Who to contact

Vanderbilt-Ingram Service for Timely Access
800-811-8480
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pathologically-proven diagnosis of melanoma.
Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible.

Exclusion

Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol.
Any patient unable or unwilling to provide consent.

What this trial measures

  • Molecular changes in patients' melanoma tissueat 120 months

    Tissue is collected upon consent or upon receipt of parafin block, primary aim will be met when all tissues are collected and analyzed at conclusion of study. Intent is to aid patients and their treating physician when making treatment decisions.